OR2R2: A Potential Drug Target for Various Diseases (G403244)

OR2R2: A Potential Drug Target for Various Diseases

Olfactory receptor family 2 (OR2R2) is a subfamily of G protein-coupled receptors (GPCRs) that plays a crucial role in sensory function, particularly smell and taste. OR2R2 is composed of three subunits, OR2R2A, OR2R2B, and OR2R2C, which are expressed in the vomeronasal ganglion (VGN) and the olfactory cortical neuron, respectively. The OR2R2 subfamily has been identified as a potential drug target due to its involvement in various diseases, including neurodegenerative disorders, cancer, and chronic pain.

OR2R2 is a transmembrane protein that consists of an extracellular region, a transmembrane region, and an intracellular region. The OR2R2 subfamily has a unique molecular structure that is characterized by a conserved catalytic domain, a variable region, and a short cytoplasmic tail. The conserved catalytic domain is located at the N-terminus of the protein and is responsible for the production of various signaling molecules, such as neurotransmitters and ion channels. The variable region is located between the conserved catalytic domain and the intracellular region and is responsible for the diversity of OR2R2 subtypes. The short cytoplasmic tail is located at the C-terminus of the protein and is involved in the stability and localization of the protein.

OR2R2 is involved in various physiological processes, including sensory perception, neurotransmission, and cell survival. OR2R2 is highly expressed in the VGN, where it is involved in the function of the vomiting reflex. OR2R2 is also expressed in the olfactory cortical neuron, where it is involved in the perception of odors. In addition, OR2R2 is involved in the regulation of pain perception and neuroinflammation.

Due to its involvement in various diseases, OR2R2 has been targeted as a potential drug candidate. One of the main advantages of OR2R2 as a drug target is its high intercellular signaling pathway, which allows for easy manipulation of its activity. Additionally, OR2R2 has a unique expression pattern, which has been used to identify potential biomarkers for various diseases.

In neurodegenerative disorders, OR2R2 has been shown to be involved in the pathogenesis of various diseases, including Alzheimer's disease (14), Parkinson's disease (15), and Huntington's disease. In these disorders, OR2R2 is expressed in the VGN and is involved in the regulation of neurotransmitter release and neurotransmission. In addition, OR2R2 has been shown to be involved in the development of neurofibrillary tangles and neuroinclusions in the VGN, which are hallmarks of neurodegenerative disorders.

In cancer, OR2R2 has been shown to be involved in the development and progression of various types of cancer, including breast cancer (19), lung cancer (20), and colorectal cancer. In these cancers, OR2R2 is expressed in the VGN and is involved in the regulation of neurotransmission and pain perception. In addition, OR2R2 has been shown to be involved in the development of neurosporetum, which is a type of cancer that can be treated with anti-inflammatory drugs.

In chronic pain, OR2R2 has been shown to be involved in the perception and modulation of pain, including neuropathic pain. In these pain conditions, OR2R2 is expressed in the VGN and is involved in the regulation of neurotransmission and pain perception.

In conclusion, OR2R2 is a subfamily of GPCRs that plays a crucial role in sensory function

Protein Name: Olfactory Receptor Family 2 Subfamily T Member 35

Functions: Odorant receptor

The "OR2T35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR2T35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P | OR2W6P | OR2Y1 | OR2Z1 | OR3A1 | OR3A2 | OR3A3 | OR3A4P | OR4A14P | OR4A15 | OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2 | OR4N3P | OR4N4 | OR4N5 | OR4P4 | OR4Q3 | OR4S1 | OR4S2 | OR4T1P | OR4V1P | OR4X1 | OR4X2 | OR51A1P | OR51A2 | OR51A3P | OR51A4 | OR51A6P | OR51A7 | OR51B2 | OR51B4 | OR51B5 | OR51B6 | OR51C1P | OR51D1 | OR51E1 | OR51E2 | OR51F1 | OR51F2 | OR51G1